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Potent antihypertrophic effect of the bradykinin B2 receptor tant role in renal development. Recent gene-targeting
system on the renal vasculature. studies in mice have confirmed this notion. Mice lacking
Background. Angiotensin type 1 (AT1) receptor-deficient both AT1A and AT1B receptor genes exhibit severemice (Agtr12/2), which selectively lack both AT1A and AT1B
renal lesions shortly after birth [4], as do mice carryingreceptor genes, are characterized by marked intrarenal vascular
thickening. In the present study, we explored the possible either the null mutated angiotensinogen (Atg) or angio-
involvement of the kinin-kallikrein system in the development tensin I-converting enzyme gene (Ace) [5–8]. Of all the
of this renal vascular hypertrophy. abnormalities described in these mutant mice, it is partic-
Methods. Wild-type and Agtr12/2 mice were examined for
ularly puzzling that the mice are hypotensive but havethe developmental regulation pattern of the kinin-kallikrein
hypertrophic renal arteriolar lesions, which are reminis-system and treated with aprotinin (a kallikrein inhibitor),
AcLys [D-b Nal7, Ile8] des-Arg9-bradykinin (a bradykinin B1 cent of the lesions of hypertensive nephrosclerosis.
receptor antagonist), or Hoe-140 (a bradykinin B2 receptor The renal kallikrein-kinin system (KKS) and renin-
antagonist) from 3 to 14 days of age.
angiotensin system both participate in the control ofResults. The normal postnatal up-regulation of kininase II
renal hemodynamics and sodium excretion [9–11]. Allwas organ-specifically suppressed in Agtr12/2 kidneys at 2
and 3 weeks of age. Immunohistochemical staining in Agtr12/2 components of the KKS, as well as those of the renin-
mice revealed tissue kallikrein staining along the nephron from angiotensin system, are present within the kidney shortly
connecting tubules to cortical collecting tubules in proximity to after birth, and both systems have been recognized asthe hypertrophic vasculature, whereas tissue kallikrein staining
vascular growth modulators [9, 12, 13]. Thus, given thewas confined to connecting tubules in wild-type mice. Aprotinin
and Hoe-140 accelerated the vascular hypertrophy significantly finding that the bradykinin B2 receptor localizes along
as determined by wall thickness ratio, whereas B1 receptor the interlobular and afferent arterioles [14], it appeared
antagonism had no effect. reasonable to speculate that the renal KKS is involvedConclusion. The kinin-kallikrein system in the Agtr12/2
in the abnormal vascular phenotype that develops in themouse kidney is functionally activated by local suppression of
kininase II and extensive redistribution of kallikrein to perivas- absence of AT1 receptor.
cular areas. This activation, specific to the kidney, serves to The aim of the present study was therefore to explore
dampen a development of the marked vascular hypertrophy. the possible involvement of the KKS in the developmentThese results demonstrate, to our knowledge for the first time,
of this renal vascular hypertrophy in Agtr12/2 mice. Bythe antihypertrophic effect of the bradykinin B2 receptor sys-
examining (1) the developmental regulation pattern oftem on the renal vasculature in vivo.
the KKS, and (2) the effect of inhibitors for kallikrein,
bradykinin B1 and bradykinin B2 receptors in Agtr12/2
Activation of the renin-angiotensin system in the de- mice, we demonstrated for the first time, to our knowledge,
veloping kidney [1–3] has led to the hypothesis that its that the bradykinin B2 receptor system exerts a potent
active component, angiotensin II (Ang II), acting via antihypertrophic effect on the renal vasculature in vivo.
angiotensin type 1 (AT1) receptor, may play an impor-
METHODS
Key words: renin-angiotensin system, kinin-kallikrein system, vascular
Micehypertrophy, bradykinin, kinase II.
Agtr1a and Agtr1b null mutant (Agtr1a2/2; Agtr1b2/2
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or Agtr12/2) mice, which are the offspring of the mutantand in revised form March 9, 1999
Accepted for publication March 16, 1999 mice generated earlier in our laboratory [4], were used
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Their genetic background is composed of 129/Ola and dogenous peroxidase was quenched by treatment in 3%
C57BL/6 strains. hydrogen peroxide. Sections were then rinsed in PBS,
labeled at room temperature for 30 minutes with rabbit
Histological analysis antihuman a-smooth muscle actin antiserum (DAKO,
Organs were fixed in 4% buffered paraformaldehyde, Carpinteria, CA, USA), and stained for five minutes with
routinely processed, embedded in paraffin, and sectioned. DAB (Research Genetics Inc., Huntsville, AL, USA).
Kidney morphology was studied by 3 mm-thick coronal This staining identified all intrarenal vasculature. After
sections stained with periodic acid Schiff. At least three a second quenching with 3% hydrogen peroxide, slides
animals of each genotype at each age were subjected to were incubated for three hours at room temperature
analyses. We examined the tissues at age zero, one, two, with rabbit antirat kallikrein antiserum (1:1000 diluted
and three weeks, which were selected based on our previ- in PBS; Calbiochem, La Jolla, CA, USA), rinsed with PBS
ous observations [4]. For studies of renal vascular mor- for 30 minutes, and treated with peroxidase-conjugated
phology, all cross sections of the interlobular arteries goat antirabbit immunoglobulin (DAKO; 1:100 diluted
were traced and examined morphometrically. Both inner in PBS). Slides were then stained with True Blue (Kir-
and outer diameters (i.d., o.d.) were measured for each kegaard and Perry Lab., Gaithersburg, MD, USA). Fi-
artery, and the wall thickness ratio [(o.d. 2 i.d.)/o.d.] nally, the slides were counterstained with Orcein (Kir-
[15] was calculated and compared between Agtr12/2 kegaard and Perry Lab) or 2% methyl green solution.
and wild-type mice. All the semiquantitative parameters As negative controls, the primary antibody was replaced
were obtained by an independent pathologist to whom by the serum of animals in which the primary antibody
no information was available regarding the identity of was developed, and the same secondary antibody was
each specimen. used.
Pharmacological inhibition of bradykinin B2 receptor, Measurements of renal ACE activity and
bradykinin B1 receptor and kallikrein kallikrein activity
Female mice mated with the male with the same geno- The activity of kallikrein in the kidneys was measured
type (Agtr1a1/2; Agtr1b2/2xAgtr1a1/2; Agtr1b2/2 with a peptidyl fluorogenic substrate selective for glandu-
or wild-typexwild-type) were carefully observed for de- lar kallikrein, D-Ser-Pro-Phe-Arg-7-amino-4-methylcou-
termination of the day of delivery. After spontaneous marin (D-PPA-AMC; Enzyme Systems Products, Liv-
delivery, newborn mouse littermates were randomly di-
ermore, CA, USA) by using a previously describedvided into four groups receiving daily subcutaneous (s.c.)
method with some modifications [20]. Briefly, kidneyinjections from 3 to 14 days of age: (i) 5% glucose vehicle;
from animals in each age group were homogenized me-(ii) a bradykinin B1 receptor antagonist, AcLys [D-b
chanically, and kallikrein was solubilized by incubatingNal7, Ile8] des-Arg9-bradykinin 300 mg per kg body wt
the whole kidney homogenates in Tris-HCl (0.1 m, pH(a generous gift from Prof. Demenico Regoli [16]); (iii)
8.2) for 20 minutes at 48C in the presence of 0.4% sodiuma bradykinin B2 receptor antagonist, Hoe 140 (D-Arg
deoxycholate followed by centrifugation at 50,000 g at[Hyp3, Thi5, D-Tic7, Oic8]-bradykinin) 600 mg per kg body
48C for 30 minutes. The supernatant was incubated withwt (a generous gift from Hoechst, Frankfurt, Germany);
0.02 mm D-PPA-AMC in 1 ml of 0.05 m Tris-HCl bufferand (iv) a kallikrein inhibitor, aprotinin 100,000 KIU per
(pH 8.2), containing 0.1 m NaCl and 0.01 m CaCl2. Afterkg body wt (Sigma). The treatment duration was deter-
incubation in a water bath for 30 minutes at 378C, themined based on the above morphometrical analyses that
reaction was stopped by the addition of 100 ml of 50%showed that the hypertrophic change is already promi-
acetic acid. One arbitrary unit (AU) was defined as thenent at the age of two weeks. The doses used in this
amount of urinary kallikrein that released 1 3 10210 molstudy have been reported by other investigators for B1
AMC for 10 minutes per mg of protein at 378C. Activeantagonist [16, 17], B2 antagonist [18], and aprotinin [19].
kallikrein activity was calculated as the difference be-The mice were weighed every morning and all drugs were
tween amidase activity in the presence of 10 mm soybeanadministered (s.c.) in equivalent volumes of 1 ml vehicle
trypsin inhibitor (SBTI; Sigma Chemical Co., St. Louis,per kg body wt. On day 14, the mice were sacrificed and
MO, USA) and that in the presence of 500 KU of aproti-the genotype was determined as previously described [4].
nin (Sigma Chemical Co.). The amidase activities in theThe postnatal survival of Agtr12/2 mice was severely
kidneys were inhibited with SBTI by 6.2 6 1.6% andcompromised as we previously described [4], although
with aprotinin by 70.7 6 10.2%. This assay method canthe treatment did not affect the survival or body weight
exclude the contamination by proteases other than kalli-in Agtr12/2 or wild-type mice (data not shown).
krein in the tissue [20]. ACE activity in the tissues was
Sequential double immunohistochemical staining measured by subsequently subjecting the homogenate
to an assay of enzymatic cleavage of hippurate fromKidney sections, from both wild-type and Agtr12/2
mice simultaneously, were dewaxed, rehydrated, and en- Hippuryl-His-Leu (Sigma Chemical Co.) as described
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elsewhere [21]. Protein concentration of the homogenate (by Hoe-140) from 3 to 14 days of age accelerated the
vascular hypertrophy in Agtr12/2 mice with luminalwas measured by the Lowry method [22].
narrowing. The vascular wall thickness ratio averaged
Northern blot analysis for ACE and 0.61 6 0.03 for vehicle-treated alone (N 5 5) versus 0.59 6
kallikrein mRNAs 0.02 for the B1 receptor antagonist (AcLys [D-b Nal7,
Ile8] des-Arg9-bradykinin)-treated (N 5 4; P . 0.05),Northern blot analysis was performed as described
0.80 6 0.02 for the B2 antagonist (Hoe-140)-treated (N 5elsewhere [23]. Briefly, RNA was isolated from kidneys,
5; P , 0.001), and 0.73 6 004 for aprotinin-treated mu-lungs, and hearts immediately after death using RNAzo-
tant mice (N 5 3; P , 0.005). In wild-type mice, theseleB (Tel.: Test Inc., Friendswood, TX, USA). Twenty
treatments were without effect (N 5 5 to 10).milligrams of RNA were electrophoresed in 1% agarose,
As there is no reliable method available today to mea-2.2 m formaldehyde and MOPS buffer gel and transferred
sure blood pressure in 14-day-old mice, the effect ofto a nylon membrane (Hybonde-N1, Amersham Life
these inhibitions on the systemic hemodynamics was notScience Inc., Arlington Heights, IL, USA). The blots were
assessed. Notably, the kidney of all Agtr12/2 mice lacksthen hybridized to random-primed 32P-labeled cDNA; a
the renal pelvis as reported earlier [26], which was notfull length mouse tissue kallikrein cDNA [24] and an
affected by any of the treatments employed.EcoRV-EcoRI fragment of the 39 end of rat endothelial
ACE cDNA [25]. Following hybridization, the mem-
Developmental pattern of ACE and kallikreinbranes were washed in 2 3 SSC (1 3 SSC; 0.15 m NaCl,
Renal ACE mRNA and its activity were developmen-0.015 m sodium citrate), and 0.2 3 SSC in 0.1% SDS.
tally upregulated in wild-type mice. This developmentalThe membrane was re-hybridized with a human glyceral-
up-regulation of ACE mRNA was markedly attenuateddehyde-3-phosphate dehydrogenase (GAPDH) cDNA
in Agtr12/2 kidneys at two and three weeks of age (Figsprobe (CLONTECH, Palo Alto, CA, USA) as a control
2 and 3). Likewise, the developmental up-regulation offor RNA loading. The band of each specific mRNA was
ACE activity was also suppressed at two and three weeksidentified and semiquantitated with an image analyzer
of age (Fig. 3). However, extrarenal ACE mRNA(Molecular Dynamics, Sunnyvale, CA, USA).
and its activity were comparable between wild-type and
Statistical analysis Agtr12/2 mice at age two weeks. Pulmonary ACE
mRNA/GAPDH ratio averaged 0.98 6 0.10 for wild-Data are presented as means 6 se. Statistical signifi-
type (N 5 4) versus 1.11 6 0.09 for Agtr12/2 (N 5 3;cance was assessed by using Mann–Whitney test and
P . 0.05), and the ACE activity (mU/min/mg protein)ANOVA followed by Tukey post hoc tests for multiple
averaged 1890 6 297 for wild-type (N 5 4) versus 1660 6comparisons. Differences were considered statistically
302 for Agtr12/2 (N 5 3; P . 0.05). Heart ACE mRNA/significant at P , 0.05.
GAPDH ratio averaged 1.71 6 0.15 for wild-type (N 5
4) versus 1.79 6 0.12 for Agtr12/2 (N 5 3; P . 0.05),
RESULTS and ACE activity (mU/min/mg protein) averaged 267 6
41 for wild-type (N 5 4) versus 234 6 19 for Agtr12/2Morphometrical analyses for developmental
(N 5 3; P . 0.05). Renal kallikrein mRNA and its activityvascular changes
were comparably up-regulated during development inMorphometrical analysis on renal arterioles in
wild-type and Agtr12/2 mice (Figs 2 and 3).Agtr12/2 mice at the age of zero, one, two, and three
weeks confirmed that the vascular thickening is some- Sequential double immunohistochemical staining
what evident at one week and became prominent after
In wild-type mice, the tissue kallikrein staining wastwo weeks. Vascular wall thickness ratio averaged 0.51 6
confined to connecting tubules (Fig. 4A). Contrastingly,0.02 for wild-type (N 5 6) versus 0.50 6 0.03 for Agtr12/2
our sequential double immunostaining for a-smooth mus-
(N 5 6; P . 0.05) at age zero weeks, 0.51 6 0.03 for cle actin and kallikrein disclosed the close proximity
wild-type (N 5 4) versus 0.57 6 0.02 for Agtr12/2 (N 5 between the hypertrophic vasculature and kallikrein-
5; P , 0.05) at age one week, 0.51 6 0.02 for wild-type containing structures in Agtr12/2 mice; tissue kallikrein
(N 5 7) versus 0.61 6 0.03 for Agtr12/2 (N 5 8; P , staining was distributed broadly with high intensity from
0.001) at age two weeks, and 0.55 6 0.04 for wild-type connecting tubules to cortical collecting tubules that
(N 5 5) versus 0.65 6 0.03 for Agtr12/2 (N 5 6; P , were directly adjacent to the hypertrophic vasculature
0.001) at age three weeks, respectively. (Fig. 4B).
Effects of pharmacological blockade of the
kinin-kallikrein system in Agtr12/2 mice DISCUSSION
As shown in Fig. 1, the pharmacological blockade of We have shown that the developmental up-regulation
of ACE, which occurs naturally in wild-type mice kid-kallikrein (by aprotinin) and the bradykinin B2 receptor
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Fig. 1. Effects of an inhibitor of bradykinin B1 receptor, bradykinin
B2 receptor or kallikrein on renal vasculature in wild-type and Agtr12/2
mice. Alpha-smooth muscle immunostaining of kidney sections shows
marked luminal narrowing (shown in arrow heads) in Agtr12/2 mice
treated with a bradykinin B2 receptor antagonist (C) or aprotinin (D),
but not with a bradykinin B1 receptor (B) antagonist or vehicle. These
treatments were without effect in wild-type mice (A) (counterstained
with methyl green, magnification 3 200). Morphometric analyses of the
wall thickness of the renal arterioles (E) in wild-type (h) and Agtr12/2
mice (j). There is increased vascular wall thickness ratio in Agtr12/2
mice that is further accentuated by the treatment with B2 receptor
antagonist or aprotinin (*P , 0.001 vs. vehicle-treated Agtr12/2 mice).
Wall thickness ratio was calculated as (o.d. 2 i.d.)/o.d.
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Fig. 2. Developmental changes in angioten-
sin converting enzyme (ACE) and kallikrein
mRNA in Northern blot analysis of wild-type
(left) and mutant (right) mice kidneys at ages
0 to 21 days. Each lane represents RNA from
one mouse.
Fig. 3. Developmental changes in renal an-
giotensin converting enzyme (ACE) mRNA
and its activity (A) and renal kallikrein mRNA
and its activity (B) in wild-type (s, h) versus
Agtr12/2 mice (d, j). Bars represent ACE
and kallikrein activities (N 5 3–7) and dots
represent ACE and kallikrein mRNA (N 5
3 to 8; *P , 0.05 vs. wild-type mice of the
same age).
neys, is organ-specifically attenuated in the kidney of kallikrein within the kidney. Taken together with the
finding that the intrarenal B2 receptor localizes withinAgtr12/2 mice. Further, we found that the kallikrein is
extensively distributed from the connecting to cortical the smooth muscle cells of interlobular and afferent arte-
rioles [14], these data suggest that in vivo bradykinincollecting tubules of perivascular areas in Agtr12/2
mice. These results raise the possibility that the intrare- has an antihypertrophic effect on the renal vasculature
through the bradykinin B2 receptor. Our findings arenal bradykinin is locally elevated along the hypertrophic
renal arterioles and serves to modulate the structure and/ reminiscent of a previous study by others demonstrating
that bradykinin, by acting on the bradykinin B2 receptor,or function of these vasculature of mutant mice. We also
found that the pharmacological blockade of kallikrein plays a role in the phenomenon in which ACE inhibitors
prevent neointimal formation after experimental injury(by aprotinin) and the B2 receptor (by Hoe-140), but
not the B1 receptor (by AcLys [D-b Nal7, Ile8] des-Arg9- to the intima of the rat carotid artery [27].
As an autocrine or paracrine hormone, bradykinin’sbradykinin), led to acceleration of the renal vascular
hypertrophy that is present in Agtr12/2 mice, although actions via its receptors need to be restricted to small,
well-defined areas. In this regard, our sequential doublethe effects observed with aprotinin may be attributed to
its inhibitory effect on serine proteases, and not on the immunostaining revealed a close proximity between the
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Fig. 4. Sequential double immunohistochemical staining of a-smooth muscle actin (*) and kallikrein (D) at age of 21 days. Mutant mice (B)
intensely express kallikrein in close proximity with the typically thickened vascular wall, contrasting to wild-type mice (A), which express kallikrein
at limited areas of connecting tubules (counterstained with Orcein, magnification 3 200).
hypertrophic vasculature and kallikrein-containing struc- the B1 receptor is also up-regulated in vascular smooth
muscle cells after vascular injury [30, 31], while it is nottures in Agtr12/2 mice, which is indeed suggestive of a
possible interaction between bradykinin and hypertro- expressed in physiological conditions. However, the B1
receptor does not appear to participate in the modulationphic arterioles. At the whole kidney level in Agtr12/2
mice, however, no significant up-regulation of kallikrein of the abnormal renal vascular phenotype in Agtr12/2
mice, since B1 receptor antagonism was without effect.mRNA or its activity was detected. The mouse renal
kallikrein gene is a member of a large homologous kalli- There is an increasing volume of evidence that Ang II,
acting via the AT1 receptor, is a potent growth promoterkrein gene family [24]. It is conceivable therefore that
this discrepancy is due to an up-regulation of other mem- for renal proximal tubular cells [32], in which ACE is
highly expressed [3]. Likewise, epidermal growth factorbers of the gene family in Agtr12/2 mice, which is insen-
sitive to immunostaining for kallikrein. Of note, the B2 (EGF) has been recognized as a growth promoter for
proximal tubules in a synergistic manner with Ang II [9].receptor has been shown to be up-regulated by the re-
lease of platelet-derived growth factor (PDGF) [13, 28, Thus, it is possible that the developmental up-regulation
of kidney ACE was attenuated due to the impaired proxi-29], which is overexpressed in the endothelial cells of
the thickened renal arterioles of angiotensinogen null mal tubular growth and/or development in Agtr12/2
mice. In support of this possibility, our most recent studymutant mice [6]. Thus, it is conceivable to speculate that
the B2 receptor is up-regulated in a highly localized on Agtr12/2 mice revealed that EGF mRNA expression
is suppressed in the mutant kidneys [26].fashion, that is, at the site of thickened arterioles, thereby
preventing development of even more marked vascular Recent observation with Ace null mutant mice indi-
cates the possibility that some of the phenotypes notedhypertrophy that would, otherwise, occur in the kidney
under this condition. Recent studies also suggest that in the absence of a functional renin angiotensin system
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7. Krege JH, John SW, Langenbach LL, Hodgin JB, Hagaman JR,may be partially due to increased level of bradykinin
Bachman ES, Jennette JC, O’Brien DA, Smithies O: Male-female
(abstract; Tian et al, J Invest Med 45:58A, 1997). In our differences in fertility and blood pressure in ACE-deficient mice.
Nature 375:146–148, 1995present study in Agtr12/2 mice, the tissue kallikrein
8. Esther CR Jr, Howard TE, Marino EM, Goddard JM, Capecchistaining was redistributed in a fashion to achieve a close
MR, Bernstein KE: Mice lacking angiotensin-converting enzyme
proximity to the hypertrophic vasculature, and the devel- have low blood pressure, renal pathology, and reduced male fertil-
ity. Lab Invest 74:953–965, 1996opmental up-regulation of a bradykinin degradation en-
9. Matsusaka T, Hymes J, Ichikawa I: Angiotensin in progressivezyme, kininase II (or ACE), was suppressed after 10
renal diseases: Theory and practice. J Am Soc Nephrol 7:2025–2043,
days of age. This postnatal time course coincides with 1996
10. Kon V, Fogo A, Ichikawa I: Bradykinin causes selective efferentthat of the development of renal vascular hypertrophy,
arteriolar dilation during angiotensin I converting enzyme inhibi-suggesting the possible involvement of bradykinin in the
tion. Kidney Int 44:545–550, 1993
process. Pharmacological blockade of bradykinin B2 re- 11. Bhoola KD, Figueroa CD, Worthy K: Bioregulation of kinins:
Kallikreins, kininogens, and kininases. Pharmacol Rev 44:1–80,ceptor from 3 to 14 days identified a potent antihypertro-
1992phic effect of bradykinin on the renal vasculature in
12. el-Dahr SS, Dipp S, Yosipiv IV, Baricos WH: Bradykinin stimu-
Agtr12/2 mice. lates c-fos expression, AP-1-DNA binding activity and prolifera-
tion of rat glomerular mesangial cells. Kidney Int 50:1850–1855,In conclusion, by examining the developmental regu-
1996lating pattern of the kinin-kallikrein system, and by as-
13. Dixon BS, Dennis MJ: Interaction of kinins and captopril in regu-
sessing the response to pharmacological inhibition of this lating arterial smooth muscle cell proliferation. Kidney Int
61(Suppl):S14–S17, 1997system in Agtr12/2 mice, we provide, to our knowledge
14. Figueroa CD, Gonzalez CB, Grigoriev S, Abd Alla SA, Haase-for the first time, in vivo evidence that the bradykinin
mann M, Jarnagin K, Muller-Esterl W: Probing for the bradyki-
B2 receptor system exerts antihypertrophic effects on nin B2 receptor in rat kidney by anti-peptide and anti-ligand anti-
bodies. J Histochem Cytochem 43:137–148, 1995the renal vasculature.
15. Matsusaka T, Nishimura H, Utsunomiya H, Kakuchi J, Niimura
F, Inagami T, Fogo A, Ichikawa I: Chimeric mice carrying ‘re-
ACKNOWLEDGMENTS gional’ targeted deletion of the angiotensin type 1A receptor gene.
Evidence against the role for local angiotensin in the in vivo feed-This work was supported by National Institutes of Health grants
back regulation of renin synthesis in juxtaglomerular cells. J ClinDK-44757, DK-37868, and HL-58205. Dr. Taiji Matsusaka is the recipi-
Invest 98:1867–1877, 1996ent of a fellowship grant from the National Kidney Foundation. Dr.
16. Gobeil F, Neugebauer W, Filteau C, Jukic D, Allogho SN,Agnes Fogo is a recipient of an Established Investigator Award from
Pheng LH, Nguyen-Le XK, Blouin D, Regoli D: Structure-activ-the American Heart Association. The authors thank Ms. Teresa Bills
ity studies of B1 receptor-related peptides. Antagonists. Hyperten-and Ms. Ellen Donnert for their superb technical assistance. The au-
sion 28:833–839, 1996thors appreciate Drs. Masataka Majima (Kitasato University of Medi-
17. Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontiscine) and Julie Chao (Medical University of South Carolina) for their
MP, Glorioso N, Dessi-Fulgheri P, Sarzani R, Anania V: Car-helpful support.
diovascular phenotype of a mouse strain with disruption of bradyki-
nin B2-receptor gene. Circulation 96:3570–3578, 1997Reprint requests to Iekuni Ichikawa, M.D., Ph.D., Vanderbilt Univer-
18. Madeddu P, Parpaglia PP, Demontis MP, Varoni MV, Fattacciosity Medical Center, MCN C-4204, 21st and Garland Avenue, Nashville,
MC, Anania V, Glorioso N: Early blockade of bradykinin B2-Tennessee 37232-2584, USA.
receptors alters the adult cardiovascular phenotype in rats. Hyper-E-mail: iekuni.i@is.icc.u-tokai.ac.jp
tension 25:453–459, 1995
19. Wang J, Xiong W, Yang Z, Davis T, Dewey MJ, Chao J, Chao
L: Human tissue kallikrein induces hypotension in transgenic mice.REFERENCES
Hypertension 23:236–243, 1994
1. Kakinuma Y, Fogo A, Inagami T, Ichikawa I: Intrarenal localiza- 20. Majima M, Yoshida O, Mihara H, Muto T, Mizogami S, Kuribay-
tion of angiotensin II type 1 receptor mRNA in the rat. Kidney ashi Y, Katori M, Oh-ishi S: High sensitivity to salt in kininogen-
Int 43:1229–1235, 1993 deficient brown Norway Katholiek rats. Hypertension 22:705–714,
2. Niimura F, Okubo S, Fogo A, Ichikawa I: Temporal and spatial 1993
expression pattern of the angiotensinogen gene in mice and rats. 21. Meng QC, Balcells E, Dellitalia L, Durand J, Oparil S: Sensi-
Am J Physiol 272:R142–R147, 1997 tive method for quantitation of angiotensin-converting enzyme
3. Jung FF, Bouyounes B, Barrio R, Tang SS, Diamant D, Ingel- (ACE) activity in tissue. Biochem Pharmacol 50:1445–1450, 1995
finger JR: Angiotensin converting enzyme in renal ontogeny: Hy- 22. Lowry O, Rosebrough N, Farr A, Randal R: Protein measure-
pothesis for multiple roles. Ped Nephrol 7:834–840, 1993 ment with the Folin phenolreagent. J Biol Chem 193:265–275, 1951
4. Tsuchida S, Matsusaka T, Chen X, Okubo S, Niimura F, Nishi- 23. Chen X, Li W, Yoshida H, Tsuchida S, Nishimura H, Takemoto
mura H, Fogo A, Utsunomiya H, Inagami T, Ichikawa I: Murine F, Okubo S, Fogo A, Matsusaka T, Ichikawa I: Targeting deletion
double nullizygotes of the angiotensin type 1A and 1B receptor of angiotensin type 1B receptor gene in the mouse. Am J Physiol
genes duplicate severe abnormal phenotypes of angiotensinogen 272:F299–F304, 1997
nullizygotes. J Clin Invest 101:755–760, 1998 24. van leeuwen BH, Evans BA, Tregear GW, Richards RI: Mouse
5. Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, glandular kallikrein genes. Identification, structure, and expression
Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O: Ge- of the renal kallikrein gene. J Biol Chem 261:5529–5535, 1986
netic control of blood pressure and the angiotensinogen locus. 25. Koike G, Krieger JE, Jacob HJ, Mukoyama M, Pratt RE, Dzau
Proc Nat Acad Sci USA 92:2735–2739, 1995 VJ: Angiotensin converting enzyme and genetic hypertension:
6. Niimura F, Labosky PA, Kakuchi J, Okubo S, Yoshida H, Oikawa Cloning of rat cDNAs and characterization of the enzyme. Biochem
T, Ichiki T, Naftilan AJ, Fogo A, Inagami T, Ichikawa I: Gene Biophy Res Com 198:380–386, 1994
targeting in mice reveals a requirement for angiotensin in the 26. Miyazaki Y, Tsuchida S, Fogo A, Ichikawa I: The renal lesions
development and maintenance of kidney morphology and growth that develop in neonatal mice during angiotensin inhibition mimic
obstructive nephropathy. Kidney Int 55:1683–1695, 1999factor regulation. J Clin Invest 96:2947–2954, 1995
Tsuchida et al: In vivo antihypertrophic effect of BK-B2 receptor516
27. Farhy RD, Carretero OA, Ho KL, Scicli AG: Role of kinins mediated relaxation in the isolated rabbit carotid artery. Eur J
Pharmacol 239:63–67, 1993and nitric oxide in the effects of angiotensin converting enzyme
31. Pruneau D, Luccarini JM, Robert C, Belichard P: Induction ofinhibitors on neointima formation. Circ Res 72:1202–1210, 1993
kinin B1 receptor-dependent vasoconstriction following balloon28. Dixon BS, Dennis MJ: Regulation of mitogenesis by kinins in
catheter injury to the rabbit carotid artery. Br J Pharmacolarterial smooth muscle cells. Am J Physiol 273:C7–C20, 1997 111:1029–1034, 1994
29. Dixon BS, Sharma RV, Dennis MJ: The bradykinin B2 receptor 32. Humes HD, Beals TF, Cieslinski DA, Sanchez IO, Page TP:
is a delayed early response gene for platelet-derived growth factor Effects of transforming growth factor-beta, transforming growth
in arterial smooth muscle cells. J Biol Chem 271:13324–13332, 1996 factor-alpha, and other growth factors on renal proximal tubule
cells. Lab Invest 64:538–545, 199130. Pruneau D, Belichard P: Induction of bradykinin B1 receptor-
